Cue Biopharma (CUE) closed at $20.87 on October 30, 2026, down 2.7% from the previous close, on volume of 60,491 shares (30-day average 350,947).
Data as of October 30, 2026.
Russell 2000 estimated to add 107 stocks in December rebalance - Stephens
Seeking Alpha News (Thu, 29-Oct 3:12 PM ET)
Market Chameleon (Mon, 21-Sep 3:05 AM ET)
Globe Newswire (Sun, 20-Sep 6:00 AM ET)
PRNewswire (Mon, 24-Aug 9:05 AM ET)
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire (Fri, 14-Aug 4:05 PM ET)
Globe Newswire (Mon, 3-Aug 8:30 AM ET)
Market Chameleon (Fri, 15-May 4:45 AM ET)
Market Chameleon (Fri, 1-May 3:05 AM ET)
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Cue Biopharma trades on the NASDAQ stock market under the symbol CUE.
As of October 30, 2026, CUE stock price declined to $20.87 with 60,491 million shares trading.
CUE has a beta of 4.61, meaning it tends to be more sensitive to market movements. CUE has a correlation of 0.10 to the broad based SPY ETF.
CUE has a market cap of $151.61 million. This is considered a Micro Cap stock.
Last quarter Cue Biopharma reported $8 million in Revenue and -$24.14 earnings per share. This beat revenue expectation by $5 million and missed earnings estimates by -$22.76.
In the last 3 years, CUE traded as high as $97.47 and as low as $4.97.
The top ETF exchange traded funds that CUE belongs to (by Net Assets): VTI, VXF, IWC, AVSC, AVTM.
CUE has underperformed the market in the last year with a return of -0.5%, while the SPY ETF gained +12.3%. In the last 3 month period, CUE fell short of the market, returning -31.3%, while SPY returned +2.1%. However, in the most recent 2 weeks CUE has outperformed the stock market by returning +24.9%, while SPY returned -1.0%.
CUE support price is $19.39 and resistance is $23.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CUE shares will trade within this expected range on the day.
